Stephen R. Davis has been leading Acadia Pharmaceuticals Inc. as their President and CEO since September 2015, bringing over 20 years of experience in the pharmaceutical sector. Before taking the helm at Acadia, he was the Executive VP and COO...

Stephen R. Davis has been leading Acadia Pharmaceuticals Inc. as their President and CEO since September 2015, bringing over 20 years of experience in the pharmaceutical sector. Before taking the helm at Acadia, he was the Executive VP and COO at Heron Therapeutics, where he helped shape a new strategy for the company. His journey includes stints at Ardea Biosciences, where he played a key role in the company's growth and development. Aside from running Acadia, he's also been involved with various boards, showing his deep commitment to the biopharmaceutical field. Under his leadership, Acadia has focused on significant product launches and achieving clinical goals, notably with drugs like NUPLAZID and DAYBUE. In 2023, his total compensation was about $1.87 million, reflecting performance-driven bonuses, stock options, and a salary of around $862,120. He also previously served in multiple executive roles at Neurogen Corporation, which gives him a well-rounded view of the industry.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Acadia Pharmaceuticals CEOs

A

Stephen R. Davis

Ex-CEO of Acadia Pharmaceuticals

Education

Not specified

Sector of Economy

Healthcare

Born

January 1, 1961 - 64 years ago

CEO of Acadia Pharmaceuticals for

9 years 0 months (Sep 2015 - Sep 2024)

Previous Experience

Executive Vice President and Chief Operating Officer at Heron Therapeutics, Inc.

Rivals

Competitors/colleagues of Stephen R. Davis

Holdings

See how much did Stephen R. Davis make over time.

Stephen R. Davis has been strategic with his holdings in Acadia Pharmaceuticals. Recently, he has increased his investment in the company, owning a large number of restricted stock units (RSUs) which greatly contribute to his overall wealth. His vested stock...

Stephen R. Davis has been strategic with his holdings in Acadia Pharmaceuticals. Recently, he has increased his investment in the company, owning a large number of restricted stock units (RSUs) which greatly contribute to his overall wealth. His vested stock in 2023 was valued at approximately $3.87 million. This reflects his commitment to Acadia and also shows how closely tied his financial success is to the company's performance. Over the years, he has held a significant number of options that were issued prior to his time as CEO, indicating he was invested in the company's future from early on. His holdings have fluctuated with the company’s stock performance, further emphasizing the alignment of leadership and shareholder interests.

Total Stock Sold

$33.32M

ACAD

$33.32M

898,413 ACAD shares

What if they kept their stock?

If Stephen R. Davis didn't sell their stock, today they would have:
Extra ACAD898,413 shares worth $37.47M.
This is 12.45% and $4.15M more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Stephen R. Davis.

ACAD

$485.09K

ACAD at $15.28/share

Aug 16, 2024

Sale

ACAD

62,115 shares

ACAD

Aug 16, 2024

Received

ACAD

$193.57K

ACAD at $16.94/share

May 1, 2024

Sale

ACAD

$474.88K

ACAD at $17.87/share

Apr 5, 2024

Sale

ACAD

$317.08K

ACAD at $17.90/share

Mar 25, 2024

Sale

ACAD

34,666 shares

ACAD

Mar 25, 2024

Received

ACAD

$137.58K

ACAD at $24.67/share

Feb 23, 2024

Sale

ACAD

$111.81K

ACAD at $29.96/share

Jan 6, 2024

Sale

ACAD

$1.13M

ACAD at $21.96/share

Oct 5, 2023

Sale

ACAD

$3.00M

ACAD at $30.04/share

Jul 14, 2023

Sale

Compensation History

See how much did Stephen R. Davis make over time.

In 2023, Stephen R. Davis’s total compensation reached approximately $1.87 million. This number includes a base salary of about $862,120, with the bulk coming from performance-based bonuses and the value of vested stock. His bonus amounted to around $886,184, which was tied to meeting corporate performance goals. Davis’s pay package follows a philosophy designed to link executive compensation with Acadia’s business performance, aiming to attract and retain top talent while aligning incentives with shareholders' interests. Notably, this compensation arrangement has fluctuated significantly over the years, reaching as high as $14.1 million in 2022, showing a strong performance correlation as Acadia progresses in the pharmaceutical landscape.

Year

2023

Total Compensation

$5.64M

Salary

$862.12K

Board Justification

The compensation philosophy is designed to align executive compensation with business objectives and corporate performance, attract and retain talent, and link compensation with stockholder interests through long-term incentives.

Bonus

$886.18K

Board Justification

The bonus is based on the achievement of corporate performance goals, with a target bonus of 80% of base salary, resulting in a payout of approximately 129% of target for 2023.

Other

$30.57K

Board Justification

Other compensation includes employer contributions to the 401(k) plan and other benefits.

Restricted Stock

$3.87M(295.5K RSU)

Board Justification

The vested stock consists of restricted stock units (RSUs) that were granted and vested in 2023.

Performance Metrics

The performance metrics for 2023 included net product sales of NUPLAZID and DAYBUE, NDA approvals, and other strategic goals.

Other Acadia Pharmaceuticals CEOs

Here are other CEOs of Acadia Pharmaceuticals

Catherine Owen Adams

CEO of Acadia Pharmaceuticals

September 2024 - Present